This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2017-2019.
Company Filing History:
Years Active: 2017-2019
Title: Steffen Gaali: Innovator in Psychiatric Treatment
Introduction
Steffen Gaali is a notable inventor based in Munich, Germany. He has made significant contributions to the field of psychiatric treatment through his innovative research and development of selective FKBP51 ligands. With a total of 2 patents, Gaali's work focuses on addressing psychiatric disorders and neurodegenerative diseases.
Latest Patents
Gaali's latest patents include compounds that feature a selective FKBP51 ligand scaffold. These compounds, along with their pharmaceutically acceptable salts, are designed for use in pharmaceutical compositions. The inventions aim to provide effective prophylaxis and treatment options for psychiatric disorders and neurodegenerative conditions. The detailed descriptions of these patents highlight their potential in advancing therapeutic strategies in mental health.
Career Highlights
Throughout his career, Steffen Gaali has worked with prestigious institutions such as the Max Planck Society for the Advancement of Science and Technische Universität Darmstadt. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his research capabilities.
Collaborations
Some of Gaali's notable coworkers include Felix Hausch and Alexander Kirschner. Their collaborative efforts have contributed to the development of innovative solutions in psychiatric treatment.
Conclusion
Steffen Gaali's work exemplifies the intersection of innovation and mental health treatment. His contributions through patents and collaborations continue to pave the way for advancements in addressing psychiatric disorders.